相关实验视频

Updated: Jul 12, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

进化医学接近慢性疾病:刺激性肠综合征的病例

Makenna B Lenover¹, Mary K Shenk¹

¹Department of Anthropology, The Pennsylvania State University, State College, Pennsylvania, USA.

Evolutionary anthropology

|November 1, 2023

概括

刺激性肠综合征 (IBS) 可能源于与现代生活方式的进化不匹配. 需要进一步的研究来探索这些进化医学假设的IBS原因.

科学领域:

进化医学是一种进化医学.
胃肠病学胃肠病学
公共卫生公共卫生

背景情况:

刺激性肠综合征 (IBS) 是一种广泛的胃肠道疾病,在工业化国家越来越普遍.
了解IBS的最终进化原因对于开发有效的预防和治疗策略至关重要.

研究的目的:

将进化医学框架应用于IBS的研究.
通过进化镜头来综合现有的IBS文献.
为IBS病因提出潜在的进化假设.

主要方法:

进行了范围范围的文献审查.
在进化医学视角中综合发现.
发现了关于进化风险因素的当前研究中的差距.

主要成果:

确定了五种IBS的潜在进化假设:饮食不匹配,改变早期生活环境 (卫生,免疫,微生物组),减少体力活动,破坏光暗周期,以及过度活跃的战斗或逃跑反应.
有关早期生命,营养和社会经济因素与进化风险相关的数据存在重大局限性.
需要进一步的经验研究来验证这些假设.

结论:

进化医学方法为IBS的潜在原因提供了宝贵的见解.
目前的数据不足以最终区分拟议的进化假设.
需要有针对性的研究来阐明IBS的进化起源,并为公共卫生干预提供信息.

关键词:

进化医学是一种进化医学.卫生假设卫生假设刺激性肠综合征是什么意思营养过渡营养过渡身体活动身体活动压力就是压力,压力就是压力.

更多相关视频

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...